MG
SCNI

Michael Gelband’s Scinai Immunotherapeutics SCNI Stock Holding History

Michael Gelband’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-32
Closed -$74K – 2620
2021
Q4 		$74K Buy
+32
New +$66K ﹤0.01% 1993

Other funds holding SCNI

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Michael Gelband's SCNI Position: Q1 2022 in Review

Michael Gelband sold out of Scinai Immunotherapeutics (SCNI) in Q1 2022, closing a stake of 32 shares — an estimated $74K sold.

Michael Gelband first reported a position in SCNI in Q4 2021 and held it in 1 quarter. The position peaked at $74K in Q4 2021. 17 funds tracked by Wall St. Rank hold SCNI as of Q1 2022.

  • Michael Gelband reported no remaining Scinai Immunotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Michael Gelband sold 32 Scinai Immunotherapeutics shares in Q1 2022, an estimated $74K.
  • Michael Gelband first reported a position in Scinai Immunotherapeutics in Q4 2021 and held it in 1 quarter.
  • Michael Gelband's Scinai Immunotherapeutics position peaked at $74K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.